Accelerate Diagnostics (MEX:AXDX) 5-Year EBITDA Growth Rate: 0.00% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AXDX Accelerate Diagnostics Inc MEX:AXDX
12 GF Score
Price MXN1.75
View Full Analysis

What is Accelerate Diagnostics 5-Year EBITDA Growth Rate?

Accelerate Diagnostics MEX:AXDX 12 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2024. GuruFocus rates MEX:AXDX with a GF Score™ of 12/100.

Accelerate Diagnostics's EBITDA per Share for the three months ended in Dec. 2024 was MXN-3.61.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Accelerate Diagnostics  (MEX:AXDX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Accelerate Diagnostics 5-Year EBITDA Growth Rate Related Terms

MEX:AXDX vs MSIU, BIOLQ, AFIB: 5-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Accelerate Diagnostics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerate Diagnostics 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's 5-Year EBITDA Growth Rate falls into.


MEX:AXDX
12GF Score
Accelerate Diagnostics Inc MEX:AXDX
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accelerate Diagnostics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Accelerate Diagnostics (MEX:AXDX) has a 5-Year EBITDA Growth Rate of 0.00% as of Dec. 2024. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' 5-Year EBITDA Growth Rate too high?
Accelerate Diagnostics' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' 5-Year EBITDA Growth Rate compare to MSIU and BIOLQ?
Accelerate Diagnostics' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Accelerate Diagnostics and its competitors. Accelerate Diagnostics's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accelerate Diagnostics Business Description

Address 3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score

Get the complete analysis for MEX:AXDX

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.75
Price